• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    宇

    宇和島市病院

    Uwajima City Hospital
    EST. 1910
    317论文总数
    5,075引用总数

    论文量&引用量时间轴

    机构学者

    论文(317)

    年份
    起
    –
    止
    排序
    1Involvement of Regulatory T Cells in the Pathophysiology of Myasthenia Gravis: from a Pediatrician's Perspective
    Masatoshi Hayashi,Koji Nagatani

    ABSTRACT Myasthenia gravis (MG) is thought to be primarily caused by autoantibodies targeting proteins at the neuromuscular junction. It has been established that autoantibodies, primarily acetylcholine receptor (AChR) antibodies, act on the neuromuscular junction, impairing neuromuscular transmission or destroying the structure of the neuromuscular junction. However, cellular immunity also plays a significant role, activating various T‐cell subsets and stimulating B cells to produce antibodies, ultimately leading to disease onset. Immune responsiveness changes throughout life. The immune system develops and matures after birth, then declines with age. At each stage, mechanisms protect the body against pathogenic microorganism invasion. It can also lead to conditions where the immune response is insufficient, even against neoplasms formed within the body. This immune response fundamentally operates through the balance between effector T (Teff) cells and regulatory T (Treg) cells. Imbalances in this equilibrium can occur during the course of MG and various other pathologies. Treatment strategies and methods often achieve therapeutic effects by normalizing this balance. In this review, from the perspective of a pediatrician who has long treated patients with not only adult MG but also childhood MG, we would like to discuss the role Treg cells play in regulating this activation of cellular immunity.

    2026Clinical and Experimental Neuroimmunology(2026)
    引用
    AI阅读
    加入学术空间
    2A Case of Neonatal Lupus Presenting with Fever and Rash in Early Infancy with Anti-Double-stranded DNA (Anti-Dsdna) Antibodies, Born to an Asymptomatic Mother Negative for Anti-Dsdna Antibodies.
    Mei Takemoto, Koji Nagatani, Sawa Tomomatsu, Hiromitsu Miura, Naoki Yakushiji

    Neonatal lupus erythematosus (NLE) is an autoimmune disorder in which maternal antibodies, particularly anti-Sjögren's-syndrome-related antigen A autoantibodies (anti-SS-A) or anti-SS-B antibodies, cause complications in foetal or neonatal cases. We report a case of NLE in an infant born to an asymptomatic mother, presenting with fever and elevated C-reactive protein despite the absence of maternal anti-double-stranded DNA (anti-dsDNA) antibodies. The patient was a 35-day-old male infant who presented with a rash and fever. Laboratory findings included elevated C-reactive protein and ferritin, soluble interleukin-2 receptor, hypocomplementaemia, and elevated D-dimer levels. NLE or urticarial vasculitis secondary to possible infantile-onset systemic lupus erythematosus was considered in the differential diagnosis. The infant and mother tested positive for anti-SS-A and anti-SS-B antibodies, with titres decreasing over time, leading to a final diagnosis of NLE. Although anti-dsDNA antibodies are typically maternal in origin, the mother in this case was repeatedly negative, making transplacental transfer unlikely and suggesting possible de novo antibody production by the infant. Although fever is rare in NLE, this case presented with systemic symptoms similar to systemic lupus erythematosus, including fever, elevated C-reactive protein, and hypocomplementaemia. In some cases of NLE, systemic symptoms similar to systemic lupus erythematosus may be observed in addition to the rash, and anti-dsDNA antibodies may also be positive serologically.

    2026Modern rheumatology case reports(2026)
    引用
    AI阅读
    加入学术空间
    3Disseminated Tuberculosis Mimicking Metastatic Cancer During Ruxolitinib Therapy for Polycythemia Vera: A Case Report and Literature Review
    Yuga Ono, Koji Oka, Kenichi Ishikawa, Hisaharu Shikata,Masahiko Kaneko

    BACKGROUND Polycythemia vera (PV) is a myeloproliferative neoplasm (MPN) characterized by erythrocytosis resulting from the clonal overproduction of hematopoietic cells in the bone marrow and is closely associated with mutations in the Janus kinase 2 (JAK2) gene. Ruxolitinib, a selective JAK1/JAK2 inhibitor used to treat MPNs, predisposes patients to opportunistic infections. Herein, we report the case of a patient with PV treated with ruxolitinib who developed disseminated tuberculosis mimicking metastatic cancer. CASE REPORT A 71-year-old woman presented with imaging findings suggestive of metastases, elevated tumor markers, and a negative interferon-γ release assay. The diagnosis was confirmed by bone biopsy and a positive sputum Mycobacterium tuberculosis polymerase chain reaction test. The patient improved with standard 4-drug antituberculous therapy. In a focused review of 35 published cases of tuberculosis occurring during ruxolitinib therapy for MPNs, disseminated disease accounted for 50% of cases, whereas PV was reported in only 3 cases. Ruxolitinib-induced immunosuppression can lead to false-negative interferon-γ release assay results, and several tumor markers, including soluble interleukin-2 receptor, neuron-specific enolase, cancer antigen (CA)125, and CA15-3, are known to be elevated in tuberculosis. CONCLUSIONS Patients with PV treated with ruxolitinib can develop active tuberculosis, including disseminated forms. When tumor markers are elevated and imaging reveals lesions suggestive of metastases, clinicians should include disseminated tuberculosis in the differential diagnosis and pursue histopathological and microbiological investigations to enable timely diagnosis and appropriate treatment.

    2026The American journal of case reports(2026)
    引用
    AI阅读
    加入学术空间
    4Hemophagocytic Lymphohistiocytosis As a Clinical Harbinger of Rapid Disease Progression in Multiple Myeloma During Daratumumab-Based Therapy.
    Hisaharu Shikata,Masahiko Kaneko,Shoichi Matsukage

    Hemophagocytic lymphohistiocytosis (HLH) is rare in patients with multiple myeloma (MM), and its significance during anti-CD38-based therapy remains unclear. We report the case of a 76-year-old man diagnosed with MM and treated with daratumumab, lenalidomide, and dexamethasone who developed HLH before an aggressive clinical relapse. Autopsy revealed diffuse extramedullary plasma cell infiltration, despite the minimal morphological evidence of hemophagocytosis. This case highlights the fact that HLH during immune-modifying therapy should be recognized as a critical clinical harbinger of rapid disease progression in patients with CLL. The early identification of HLH is vital for detecting imminent disease progression and initiating immediate intervention before massive systemic involvement occurs.

    2026Internal medicine (Tokyo, Japan)(2026)
    引用
    AI阅读
    加入学术空间
    5A Case of Cryofibrinogenemia Presenting with Skin Ulcers Following Cold Exposure
    Yu IMURA,Satoshi YOSHIDA, Nobushige KORI,Katsuhiko NISHIHARA,Kazuki YATSUZUKA,Jun MUTO,Ken SHIRAISHI, Mari IWATA, Haruna ASANO, Takatsugu HONDA,Yasuhiro FUJISAWA
    2026The Nishinihon Journal of Dermatology(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 317 篇论文

    合作机构(100)

    爱媛大学合作论文 78
    愛媛県立中央病院合作论文 37
    Saiseikai Matsuyama Hospital合作论文 21
    京都大学合作论文 16
    松山赤十字病院合作论文 15
    东京大学合作论文 13
    大阪大学合作论文 12
    庆应义塾大学合作论文 12
    金泽大学合作论文 12
    日本大学合作论文 10

    机构统计